Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients

Journal of Endocrinological Investigation

Volumn 31, Issue 8, 2008, Pages 704-710

  Attanasio, Roberto ^a,b,e   Mainolfi, A ^c   Grimaldi, F ^d   Cozzi, R ^e   Montini, M ^a   Carzaniga, C ^f   Grottoli, S ^c   Cortesi, L ^a   Albizzi, M ^a   Testa, R M ^a,g   Fatti, L ^f   de Giorgio, D ^c   Scaroni, C ^g   Cavagnini, F ^f   Loli, P ^e   Pagani, G ^a   Ghigo, E ^c  

^a OSPEDALI RIUNITI   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e Department of Endocrinology Ospedale Niguarda ^*  (Italy)

^f ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acromegaly; Gallstones; GH; IGF I; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; LONG ACTING DRUG; OCTREOTIDE; SHORT ACTING DRUG; SOMATOSTATIN DERIVATIVE; URSODEOXYCHOLIC ACID;

ACROMEGALY; ADULT; ARTICLE; CHOLECYSTECTOMY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GALLSTONE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; RETROSPECTIVE STUDY; STEATOSIS;

EID: 56249120975     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346419     Document Type: Article

References (58)

1. Melmed S. Acromegaly. N Engl J Med 2006, 355: 2558-73.
2. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970, 39: 1-16.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004, 25: 102-52.
4. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
5. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293-9.
6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41: 95-102.
7. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
8. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004, 89: 2789-96.
9. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74.
10. Kauppinen-Mäkelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081-6.
11. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465-73.
12. Cozzi R, Attanasio R. Octreotide for acromegaly. Expert Rev Endocrinol Metab 2007, 2: 129-45.
13. Redfern JS, Fortuner WJ 2nd. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995, 90: 1042-52.
14. Peng WK, Sheikh Z, Paterson-Brown S, Nixon SJ. Role of liver function tests in predicting common bile duct stones in acute calculous cholecystitis. Br J Surg 2005, 92: 1241-7.
15. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001, 77: 221-9.
16. Mittal B, Mittal RD. Genetics of gallstone disease. J Postgrad Med 2002, 48: 149-52.
17. Tseng M, Everhart JE, Sandler RS. Dietary intake and gallbladder disease: a review. Public Health Nutrition 1999, 2: 161-72.
18. Dowling RH. Review: pathogenesis of gallstones. Aliment Pharmacol Ther 2000, 14 (Suppl 2): 39-47.
19. Cuevas A, Miquel JF, Reyes MS, Zanlungo S, Nervi F. Diet as a risk factor for cholesterol gallstone disease. J Amer Coll Nutr 2004, 23: 187-96.
20. Hofmann AF. Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones. Gut 2005, 54: 575-8.
21. Marcus SN, Heaton KW. Deoxycholic acid and the pathogenesis of gallstones. Gut 1988, 29: 522-33.
22. Marcus SN, Heaton KW. Intestinal transit, deoxycholic acid, and the cholesterol saturation of bile: three inter-related factors. Gut 1986, 27: 550-8.
23. Veysey MJ, Thomas LA, Mallet AI, et al. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut 1999, 44: 675-81.
24. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of somatostatin analogue sandostatin (SMS 201-995) on gastro-intestinal, pancreatic, and biliary function, and hormone release in normal men. Digestion 1987, 36: 108-24.
25. Fisher RS, Rock E, Levin G, Malmud L. Effect of somatostatin on gallbladder emptying. Gastroenterology 1987, 92: 885-90.
26. Moschetta A, Stolk MF, Rehfeld JF, et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001, 15: 181-5.
27. John KD, Ballantyne GH, Modlin IM. Octreotide acetate inhibits motility in the rabbit distal colon. Eur Surg Res 1997, 29: 311-8.
28. Stacpoole PW, Kasselberg AG, Berelowitz M, Chey WY. Somatostatinoma syndrome: does a clinical entity exist? Acta Endocrinol 1983, 102: 80-7.
29. McKnight JA, McCance DR, Crothers JG, Atkinson AB. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. BMJ 1989, 299: 604-5.
30. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA. Gallstones during octreotide therapy. Metabolism 1992, 41 (Suppl 2): 22-33.
31. Hussaini SH, Murphy GM, Kennedy C, Besser GM, Wass JA, Dowling RH. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology 1994, 107: 1503-13.
32. Plöckinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment with acromegaly. J Ciin Endocrinol Metab 1990, 71: 1658-62.
33. Catnach SM, Anderson JV, Fairclough PD, et al. Effect of octreotide on gallstone prevalence and gallbladder motility in acromegaly. Gut 1993, 34: 270-3.
34. Montini M, Gianola D, Pagani MD, et al. Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol 1994, 40: 401-6.
35. Thomas LA, Veysey MJ, Murphy GM, et al. Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut 2005, 54: 630-5.
36. Erlinger S, Chanson P, Dumont M, et al. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study. Dig Dis Sci 1994, 39: 2384-8.
37. Olivecrona H, Ericsson S, Angelin B. Growth hormone treatment does not alter biliary lipid metabolism in healthy adult man. J Clin Endocrinol Metab 1995, 80: 1113-7.
38. Heubi JE, Burstein S, Sperling MA, Gregg D, Subbiah MT, Matthews DE. The role of human growth hormone in the regulation of cholesterol and bile acid metabolism. J Clin Endocrinol Metab 1983, 57: 885-91.
39. Turner HE, Lindsell DRM, Vadivale A, Thillainayagam AV, Wass JAH. Differing effects on gallbladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol 1999, 141: 590-4.
40. Hussaini SH, Pereira SP, Veysey MJ, et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide-induced gall bladder stones. Gut 1996, 38: 775-83.
41. Thomas LA, Veysey MJ, Bathgate T, et al. Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis. Gastroenterology 2000, 119: 806-15.
42. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. Gut 1997, 41: 245-51.
43. Hussaini SH, Pereira SP, Murphy GM, Dowling RH. Deoxycholic acid influences cholesterol solubilization and microcrystal nucleation time in gallbladder bile. Hepatology 1995, 22: 1735-44.
44. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996, 334: 246-54.
45. Stolk MFJ, van Erpecum KJ, Koppeschaar HPF, et al. Postprandial gall bladder motility and hormone release during intermittent and continuous octreotide therapy in acromegaly. Gut 1993, 34: 808-13.
46. Tauber JP, Poncet MF, Harris AG, et al. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients. J Clin Endocrinol Metab 1995, 80: 3262-6.
47. Chanson F, Leselbaum A, Blumberg J, Schaison G. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2000, 2: 269-76.
48. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegaiy patients. Sandostatin LAR Group. Pituitary 1999, 1: 105-14.
49. Avila NA, Shawker TH, Roach P, Bradford MH, Skarulis MC, Eastman R. Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: incidence and time course. J Clin Ultrasound 1998, 26: 289-94.
50. Shi YF, Zhu XF, Harris AG, Zhang JX, Deng JY. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients. Acta Endocrinol (Copenh) 1993, 129: 207-12.
51. Sadoul JL, Benchimol D, Thyss A, Freychet P. Acute pancreatitis following octreotide withdrawal. Am J Med 1991, 90: 763-4.
52. Rhodes M, James RA, Bird M, Clayton B, Kendall-Taylor P, Lennard TW. Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment. Scand J Gastroenterol 1992, 27: 115-8.
53. Paisley AN, Roberts ME, Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol 2007, 66: 723-6.
54. Attili AF, De Santis A, Capri R, Repice AM, Maselli S. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology 1995, 21: 655-60.
55. Fromm H, Malavolti M. Bile acid dissolution therapy of gallbladder stones. Baillieres Clin Gastroenterol 1992, 6: 689-95.
56. Petroni ML, Jazrawi RP, Pazzi P, et al. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group. Aliment Pharmacol Ther 2001, 15: 123-8.
57. Hussaini SH, Pereira SP, Murphy GM, et al. Composition of gall bladder stones associated octreotide: response to oral ursodeoxycholic acid. Gut 1995, 36: 126-32.
58. Paumgartner G, Sauerbruch T. Gallstones: pathogenesis. Lancet 1991, 338: 1117-21.